https://www.alsaventures.com https://www.alsaventures.com/our-approach https://www.alsaventures.com/meet-the-team https://www.alsaventures.com/portfolio https://www.alsaventures.com/news https://www.alsaventures.com/investor-portal https://www.alsaventures.com/privacy-policy https://www.alsaventures.com/terms-of-use https://www.alsaventures.com/eclipse/summary https://www.alsaventures.com/eclipse/eclipse-application https://www.alsaventures.com/eclipse/learn-more https://www.alsaventures.com/blog https://www.alsaventures.com/all-news https://www.alsaventures.com/sfdr-disclosure https://www.alsaventures.com/remuneration-policy https://www.alsaventures.com/news/a-venture-capital-investors-take-on-the-uk-life-sciences-funding-environment---with-alek-safarian-of-alsa-ventures https://www.alsaventures.com/news/aacr-2022-oxford-biotherapeutics-to-present-potential-novel-immuno-oncology-mechanism-in-combination-with-checkpoint-inhibitors-for-experimental-adc-medicine-obt076 https://www.alsaventures.com/news/alsa-ventures-appoints-dr-bruce-goldsmith-as-operating-partner https://www.alsaventures.com/news/alsa-ventures-closes-us-59-million-european-biotech-venture-capital-fund https://www.alsaventures.com/news/alsa-ventures-launches-european-biotech-clinical-accelerator-eclipse-to-speed-preclinical-assets-into-the-clinic https://www.alsaventures.com/news/alsa-ventures-launches-novel-gene-therapy-portfolio-company-axovia-therapeutics-to-treat-ciliopathies https://www.alsaventures.com/news/alsa-ventures-launches-vantage-biosciences-to-treat-diabetic-eye-disease https://www.alsaventures.com/news/alsa-ventures-webinar https://www.alsaventures.com/news/alsa-ventures-webinar-investing-in-biotechnology-in-the-covid-era https://www.alsaventures.com/news/axovia-therapeutics-and-rhythm-pharmaceuticals-announce-joint-research-collaboration-in-bardet-biedl-syndrome https://www.alsaventures.com/news/bioneex-and-alsa-ventures-partner-to-provide-biotech-firms-a-new-way-to-drug-candidate-out-licensing-and-acquiring-investment https://www.alsaventures.com/news/boehringer-ingelheim-acquires-fourth-license-for-the-development-of-novel-antibody-based-cancer-treatments-from-oxford-biotherapeutics https://www.alsaventures.com/news/boehringer-ingelheim-and-oxford-biotherapeutics-expand-collaboration-to-discover-novel-selective-tumor-targets-as-first-bispecific-antibody-advanced-into-the-clinic https://www.alsaventures.com/news/boehringer-ingelheim-and-oxford-biotherapeutics-partnership-advances-second-oncology-drug-candidate-into-the-clinic https://www.alsaventures.com/news/epsilogen-announces-acquisition-of-tigatx-inc-to-create-worlds-leading-pan-isotype-cancer-antibody-company https://www.alsaventures.com/news/epsilogen-announces-completion-of-oversubscribed-ps30-75-million-41-20-million-series-b-financing https://www.alsaventures.com/news/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer https://www.alsaventures.com/news/epsilogen-announces-initiation-of-phase-ib-trial-of-mov18-ige https://www.alsaventures.com/news/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer https://www.alsaventures.com/news/epsilogen-appoints-ashley-nagle-as-chief-business-officer-and-peter-finan-as-non-executive-chairman-as-part-of-broader-company-expansion https://www.alsaventures.com/news/epsilogen-press-release https://www.alsaventures.com/news/epsilogen-press-release-2 https://www.alsaventures.com/news/epsilogen-press-release-3 https://www.alsaventures.com/news/epsilogen-press-release-4 https://www.alsaventures.com/news/epsilogen-smart-grant https://www.alsaventures.com/news/featured-article-on-endpoints-news https://www.alsaventures.com/news/featured-article-on-eurekalert https://www.alsaventures.com/news/igem-therapeutics-press-release https://www.alsaventures.com/news/investing-in-women-code https://www.alsaventures.com/news/kite-obt-press-release https://www.alsaventures.com/news/lonza-and-alsa-ventures-collaborate-to-provide-development-and-manufacturing-services-for-biotech-firms https://www.alsaventures.com/news/montis-biosciences-appoints-karen-zinkewich-peotti-as-chief-executive-officer https://www.alsaventures.com/news/montis-biosciences-appoints-rene-hoet-as-chief-scientific-officer https://www.alsaventures.com/news/montis-biosciences-awarded-vlaio-grant-to-expand-its-pipeline-of-novel-immune-oncology-therapeutics https://www.alsaventures.com/news/montis-biosciences-press-release https://www.alsaventures.com/news/nature-article-cites-ige-antibodies-as-a-technology-to-watch-in-2021-and-notes-their-potential-as-an-anti-cancer-therapy https://www.alsaventures.com/news/obt-news https://www.alsaventures.com/news/oxford-bio-therapeutics-press-release https://www.alsaventures.com/news/oxford-biotherapeutics-announces-collaboration-with-agenus-to-support-the-clinical-development-of-obts-antibody-drug-conjugate-obt076-in-combination-with-agenus-cpi-balstilimab https://www.alsaventures.com/news/oxford-biotherapeutics-announces-partner-boehringer-ingelheim-dosed-first-patient-in-phase-2-trial-with-bi-764532-in-small-cell-lung-cancer-and-other-neuroendocrine-cancers https://www.alsaventures.com/news/oxford-biotherapeutics-announces-partner-boehringer-ingelheim-received-u-s-fda-fast-track-designation-for-bi-764532-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-and-extrapulmonary-neuroendocrine-cancers https://www.alsaventures.com/news/oxford-biotherapeutics-announces-research-collaboration-with-immunogen-to-develop-novel-antibody-drug-conjugates https://www.alsaventures.com/news/oxford-biotherapeutics-enters-into-a-strategic-collaboration-with-gsk-to-discover-novel-targets-for-antibody-based-therapeutics-for-the-treatment-of-cancer https://www.alsaventures.com/news/oxford-biotherapeutics-enters-into-a-strategic-collaboration-with-roche-to-discover-novel-targets-for-antibody-based-therapeutics-for-the-treatment-of-cancer https://www.alsaventures.com/news/oxford-biotherapeutics-enters-into-commercial-license-agreement-with-genmab https://www.alsaventures.com/news/oxford-biotherapeutics-grants-third-exclusive-license-to-boehringer-ingelheim-for-development-and-commercialization-of-antibody-products-to-a-novel-oncology-target https://www.alsaventures.com/news/oxford-biotherapeutics-obt-announces-second-oncology-drug-candidate-selected-to-advance-into-formal-ind-enabling-studies-from-boehringer-ingelheim-bi-collaboration https://www.alsaventures.com/news/oxford-biotherapeutics-to-present-initial-positive-data-from-phase-i-trial-at-asco-2022 https://www.alsaventures.com/news/promatix-and-jasmin-fisher-lab-at-university-college-london-accelerate-hunt-for-oncology-therapeutics-with-new-algorithms-for-cipherpro https://www.alsaventures.com/news/promatix-biosciences-presents-positive-preclinical-data-with-first-in-class-pbs293-egfrxepha2-cis-bispecific-adc-demonstrating-enhanced-tumour-selectivity https://www.alsaventures.com/news/promatix-launches-to-develop-next-generation-novel-oncology-therapeutics https://www.alsaventures.com/news/repronovo-announces-first-participant-included-in-u-s-phase-2-trial-of-rpn-001-for-male-infertility https://www.alsaventures.com/news/repronovo-raises-65-million-series-a-financing-to-advance-phase-2-clinical-trials-of-novel-therapies-in-reproductive-medicine-and-womens-health https://www.alsaventures.com/news/vantage-biosciences-doses-first-patient-in-phase-2-clinical-study-of-oral-vx-01-for-non-proliferative-diabetic-retinopathy https://www.alsaventures.com/post/european-biotech-2020-a-review https://www.alsaventures.com/post/has-covid-19-changed-the-investing-habits-of-venture-capitalists https://www.alsaventures.com/post/why-invest-in-european-biotech